Form 4: Surgery Partners Executive Harrison R. Bane Reports Stock Transactions

Harrison R. Bane, National Group President at Surgery Partners, Inc., reports acquisition and disposal of company stock related to restricted stock awards and tax obligations.

Summary

• On September 1, 2024, Harrison R. Bane acquired 1,251 shares of Surgery Partners, Inc. common stock at $31.95 per share as part of a restricted stock award.
• These restricted stock awards vest in three equal annual installments starting on the first anniversary of the grant date.
• On September 4, 2024, Bane sold 6,325 shares at $31.1054 per share.
• The sale was to cover tax withholding obligations associated with the vesting of restricted stock on September 1, 2024.
• Following these transactions, Bane directly owns 48,236 shares of Surgery Partners, Inc.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are routine and related to executive compensation and tax obligations. No strong positive or negative signals are apparent.

Positives

• The acquisition of restricted stock indicates confidence in the company's future performance.

Negatives

• The sale of shares, while for tax obligations, could be perceived negatively by some investors.

Risks

• Executive stock sales, even for tax purposes, can sometimes create short-term price volatility.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the restricted stock awards suggests a multi-year commitment from the executive.

Industry Context

Insider transactions are common and closely monitored in the healthcare industry, particularly for companies like Surgery Partners operating in the ambulatory surgery center (ASC) space. These transactions can provide insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• Monitoring insider transactions is a standard practice in financial analysis, especially in the healthcare sector.
• Comparable companies like AmSurg and United Surgical Partners International also see regular Form 4 filings from their executives.
• The vesting schedule of the restricted stock is typical for executive compensation packages in the industry, aligning management's interests with long-term shareholder value.

Stakeholder Impact

• The transactions have a minor impact on shareholders, primarily through potential short-term price fluctuations due to the stock sale.

Key Dates